Literature DB >> 1233247

Binding of amobarbital, pentobarbital and diphenylhydantoin to blood cells and plasma proteins in healthy volunteers and uraemic patients.

M Ehrnebo, I Odar-Cederlöf.   

Abstract

By equilibrium dialysis of human plasma it has been shown that the binding of pentobarbital and diphenylhydantoin to plasma proteins is decreased in uraemic patients (46 and 74 per cent bound, respectively) compared to healthy volunteers (61 and 88 per cent bound). The degree of binding of pentobarbital was significantly correlated with that of diphenylhydantoin and amobarbital, which suggests similarity of their binding sites. Appreciable proportions of the drugs were found in blood cells both in healthy and uraemic subjects. As expected, the distribution of drugs in whole blood was different in the uraemics from healthy subjects, because of the decreased plasma protein binding and the lowered red cell count in uraemia. Analysis of the data showed that the ratio between the concentrations in blood cells and plasma water in uraemic patients was not significantly different from that in healthy subjects.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1233247     DOI: 10.1007/bf00562320

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  21 in total

1.  Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.

Authors:  M M Reidenberg; I Odar-Cederlöf; C von Bahr; O Borgå; F Sjöqvist
Journal:  N Engl J Med       Date:  1971-07-29       Impact factor: 91.245

2.  Pentazocine binding to blood cells and plasma proteins.

Authors:  M Ehrnebo; S Agurell; L O Boréus; E Gordon; U Lönroth
Journal:  Clin Pharmacol Ther       Date:  1974-09       Impact factor: 6.875

3.  Effect of protein binding on the distribution of 5,5-diphenylhydantoin between plasma and red cells.

Authors:  P Borondy; W A Dill; T Chang; R A Buchanan; A J Glazko
Journal:  Ann N Y Acad Sci       Date:  1973-11-26       Impact factor: 5.691

4.  Kinetics of diphenylhydantoin in uraemic patients: consequences of decreased plasma protein binding.

Authors:  I Odar-Cederlöf; O Borgå
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

5.  Effects of psychotropic drugs on the erythrocyte permeability to glucose and ethylidene glucose.

Authors:  G F Baker; H J Rogers
Journal:  Biochem Pharmacol       Date:  1972-07-01       Impact factor: 5.858

6.  The alteration of plasma proteins in uremia as reflected in their ability to bind digitoxin and diphenylhydantoin.

Authors:  D W Shoeman; D L Azarnoff
Journal:  Pharmacology       Date:  1972       Impact factor: 2.547

7.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

8.  Anemia in uremia. Hemolysis evaluated by common methods and application of the bilirubin turnover method.

Authors:  S G Eklund; S V Johansson; O Strandberg
Journal:  Acta Med Scand       Date:  1971-11

9.  Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults.

Authors:  M Ehrnebo; S Agurell; B Jalling; L O Boréus
Journal:  Eur J Clin Pharmacol       Date:  1971-09       Impact factor: 2.953

10.  Complex formation between macromolecules and drugs. IX. The competition between two sulfa drugs and phenobarbital, pentobarbital or phenoxymethyl penicillin for binding sites on human serum albumin.

Authors:  S O Nilsson; A Agren; J O Brånstad; U Meresaar
Journal:  Acta Pharm Suec       Date:  1973-12
View more
  25 in total

Review 1.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

2.  [Pharmaco-kinetic aspects of protein-binding (author's transl)].

Authors:  H Kurz
Journal:  Klin Wochenschr       Date:  1978-12-15

3.  Plasma protein binding of phenytoin and warfarin in patients undergoing renal transplantation.

Authors:  I Odar-Cederlof
Journal:  Clin Pharmacokinet       Date:  1977 Mar-Apr       Impact factor: 6.447

4.  The EMIT FreeLevel ultrafiltration technique compared with equilibrium dialysis and ultracentrifugation to determine protein binding of phenytoin.

Authors:  M Oellerich; H Müller-Vahl
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

Review 5.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

Review 6.  Clinical pharmacokinetic considerations in the treatment of increased intracranial pressure.

Authors:  G Heinemeyer
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447

7.  Distribution of pentobarbital and diphenylhydantoin between plasma and cells in blood: effect of salicylic acid, temperature and total drug concentration.

Authors:  M Ehrnebo; I Odar-Cederlöf
Journal:  Eur J Clin Pharmacol       Date:  1977       Impact factor: 2.953

8.  Pethidine binding in whole blood: methodology and clinical significance.

Authors:  C La Rosa; D J Morgan; L E Mather
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

9.  Pethidine binding to blood cells and plasma proteins in old and young subjects.

Authors:  L Holmberg; I Odar-Cederlöf; J L Nilsson; M Ehrnebo; L O Boréus
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 10.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.